193 related articles for article (PubMed ID: 16734808)
1. Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile.
Levy JH; Fingerhut A; Brott T; Langbakke IH; Erhardtsen E; Porte RJ
Transfusion; 2006 Jun; 46(6):919-33. PubMed ID: 16734808
[TBL] [Abstract][Full Text] [Related]
2. Safety profile of recombinant factor VIIa.
Roberts HR; Monroe DM; Hoffman M
Semin Hematol; 2004 Jan; 41(1 Suppl 1):101-8. PubMed ID: 14872430
[TBL] [Abstract][Full Text] [Related]
3. Is the use of rFVIIa safe and effective in bleeding neonates? A retrospective series of 8 cases.
Mitsiakos G; Papaioannou G; Giougi E; Karagianni P; Garipidou V; Nikolaidis N
J Pediatr Hematol Oncol; 2007 Mar; 29(3):145-50. PubMed ID: 17356391
[TBL] [Abstract][Full Text] [Related]
4. Recombinant factor VIIa (Novoseven) and the safety of treatment.
Roberts HR
Semin Hematol; 2001 Oct; 38(4 Suppl 12):48-50. PubMed ID: 11735111
[TBL] [Abstract][Full Text] [Related]
5. Ongoing NovoSeven trials.
Erhardtsen E
Intensive Care Med; 2002 Oct; 28 Suppl 2():S248-55. PubMed ID: 12404094
[TBL] [Abstract][Full Text] [Related]
6. A novel hemostatic agent: the potential role of recombinant activated factor VII (rFVIIa) in anesthetic practice.
Murkin JM
Can J Anaesth; 2002 Dec; 49(10):S21-6. PubMed ID: 12546007
[TBL] [Abstract][Full Text] [Related]
7. Recombinant factor VIIa improves coagulopathy caused by liver failure.
Brown JB; Emerick KM; Brown DL; Whitington PF; Alonso EM
J Pediatr Gastroenterol Nutr; 2003 Sep; 37(3):268-72. PubMed ID: 12960648
[TBL] [Abstract][Full Text] [Related]
8. Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy.
Shami VM; Caldwell SH; Hespenheide EE; Arseneau KO; Bickston SJ; Macik BG
Liver Transpl; 2003 Feb; 9(2):138-43. PubMed ID: 12548507
[TBL] [Abstract][Full Text] [Related]
9. Reversal of coagulopathy in critically ill patients with traumatic brain injury: recombinant factor VIIa is more cost-effective than plasma.
Stein DM; Dutton RP; Kramer ME; Scalea TM
J Trauma; 2009 Jan; 66(1):63-72; discussion 73-5. PubMed ID: 19131807
[TBL] [Abstract][Full Text] [Related]
10. Effective management of refractory postcardiotomy bleeding with the use of recombinant activated factor VII.
Filsoufi F; Castillo JG; Rahmanian PB; Scurlock C; Fischer G; Adams DH
Ann Thorac Surg; 2006 Nov; 82(5):1779-83. PubMed ID: 17062247
[TBL] [Abstract][Full Text] [Related]
11. The clinical and laboratory response to recombinant factor VIIA in trauma and surgical patients with acquired coagulopathy.
McMullin NR; Kauvar DS; Currier HM; Baskin TW; Pusateri AE; Holcomb JB
Curr Surg; 2006; 63(4):246-51. PubMed ID: 16843774
[TBL] [Abstract][Full Text] [Related]
12. Recombinant factor VIIa in the treatment of bleeding.
Midathada MV; Mehta P; Waner M; Fink LM
Am J Clin Pathol; 2004 Jan; 121(1):124-37. PubMed ID: 14750250
[TBL] [Abstract][Full Text] [Related]
13. Recombinant-activated coagulation factor VIIa (NovoSeven): current development.
Weiskopf RB
Vox Sang; 2007 May; 92(4):281-8. PubMed ID: 17456151
[TBL] [Abstract][Full Text] [Related]
14. Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma.
Martinowitz U; Kenet G; Lubetski A; Luboshitz J; Segal E
Can J Anaesth; 2002 Dec; 49(10):S15-20. PubMed ID: 12546003
[TBL] [Abstract][Full Text] [Related]
15. Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries.
Martinowitz U; Holcomb JB; Pusateri AE; Stein M; Onaca N; Freidman M; Macaitis JM; Castel D; Hedner U; Hess JR
J Trauma; 2001 Apr; 50(4):721-9. PubMed ID: 11303171
[TBL] [Abstract][Full Text] [Related]
16. Recombinant activated factor VII (NovoSeven): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding.
Mayo A; Misgav M; Kluger Y; Geenberg R; Pauzner D; Klausner J; Ben-Tal O
Vox Sang; 2004 Jul; 87(1):34-40. PubMed ID: 15260820
[TBL] [Abstract][Full Text] [Related]
17. Low-dose recombinant factor VIIa for trauma patients with coagulopathy.
Stein DM; Dutton RP; Hess JR; Scalea TM
Injury; 2008 Sep; 39(9):1054-61. PubMed ID: 18656871
[TBL] [Abstract][Full Text] [Related]
18. FVIIa corrects the coagulopathy of fulminant hepatic failure but may be associated with thrombosis: a report of four cases.
Pavese P; Bonadona A; Beaubien J; Labrecque P; Pernod G; Letoublon C; Barnoud D
Can J Anaesth; 2005 Jan; 52(1):26-9. PubMed ID: 15625252
[TBL] [Abstract][Full Text] [Related]
19. Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency.
Brenner B; Wiis J
Hematology; 2007 Feb; 12(1):55-62. PubMed ID: 17364994
[TBL] [Abstract][Full Text] [Related]
20. Use of recombinant factor VIIa in infants with severe coagulopathy.
Fontaine MJ; Lazarchick J; Taylor S; Annibale D
J Perinatol; 2004 May; 24(5):310-1. PubMed ID: 15116125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
